| scholarly article | Q13442814 |
| P50 | author | Peter M. Fischer | Q39590015 |
| P2093 | author name string | George Kontopidis | |
| Andy Plater | |||
| Angela Cowan | |||
| Campbell McInnes | |||
| Lorraine Innes | |||
| Philip Jewsbury | |||
| Martin J I Andrews | |||
| P2860 | cites work | Cyclin A1 is required for meiosis in the male mouse | Q22008479 |
| Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex | Q24336704 | ||
| Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation | Q24607335 | ||
| Processing of X-ray diffraction data collected in oscillation mode | Q26778468 | ||
| Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
| The CCP4 suite: programs for protein crystallography | Q27861090 | ||
| Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF | Q28298995 | ||
| Differential regulation of E2F transactivation by cyclin/cdk2 complexes | Q28612933 | ||
| Principles of CDK regulation | Q29547820 | ||
| MOLREP: an Automated Program for Molecular Replacement | Q29642797 | ||
| Docking: successes and challenges | Q33389996 | ||
| Molecular properties that influence the oral bioavailability of drug candidates | Q34130727 | ||
| Peptidomimetics and peptide backbone modifications | Q34948444 | ||
| Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit | Q35101061 | ||
| Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists | Q35124562 | ||
| The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases | Q35794186 | ||
| Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. | Q44105387 | ||
| LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites | Q44247315 | ||
| Proliferation of cancer cells despite CDK2 inhibition. | Q44391102 | ||
| Do cells need CDK2 and ... Bcr-Abl? | Q44699399 | ||
| Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. | Q48823384 | ||
| Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. | Q52523363 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1909-1915 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | ChemBioChem | Q634395 |
| P1476 | title | REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors | |
| P478 | volume | 7 |
| Q44840359 | Antitumor activity of novel chimeric peptides derived from cyclinD/CDK4 and the protein transduction domain 4. |
| Q38764692 | Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy |
| Q57696757 | Bifunctional up-converting lanthanide nanoparticles for selective in vitro imaging and inhibition of cyclin D as anti-cancer agents |
| Q28250447 | Cell cycle kinases as therapeutic targets for cancer |
| Q55315041 | Computer-aided design of amino acid-based therapeutics: a review. |
| Q38211244 | Current assessment of polo-like kinases as anti-tumor drug targets. |
| Q36186117 | Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics |
| Q35837170 | Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. |
| Q51075716 | Effect of electrostatic polarization and bridging water on CDK2-ligand binding affinities calculated using a highly efficient interaction entropy method. |
| Q35685158 | Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones |
| Q37566871 | Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors |
| Q28534360 | Identification and structural-functional analysis of cyclin-dependent kinases of the cattle tick Rhipicephalus (Boophilus) microplus |
| Q35855056 | Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1). |
| Q35100606 | Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity |
| Q38914630 | Mimicking Peptides… In Silico |
| Q36955164 | Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly |
| Q41569041 | Peptide-Directed Binding for the Discovery of Modulators of α-Helix-Mediated Protein-Protein Interactions: Proof-of-Concept Studies with the Apoptosis Regulator Mcl-1. |
| Q90787943 | Peptidomimetic Polo-Box targeted inhibitors that engage PLK1 in tumor cells and are selective against the PLK3 tumor suppressor |
| Q42287755 | Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements |
| Q43091367 | Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype |
| Q35542088 | Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors |
| Q27655620 | Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design |
Search more.